RBC Capital raised the firm's price target on Concentra to $31 from $30 and keeps an Outperform rating on the shares. The firm cites the company's above-consensus Q4 pre-announcement and initial FY26 guide, the analyst tells investors in a research note. The solid Q4 print reflects inherent stability in the business model, even amid macroeconomic uncertainty, the firm added.
